Inda A M, Andrini L B, García M N, García A L, Fernández Blanco A, Furnus C C, Galletti S M, Prat G D, Errecalde A L
Cátedra de Citología, Histología y Embriología A, Facultad de Ciencias Médicas, UNLP, La Plata, Argentina.
J Exp Clin Cancer Res. 2007 Sep;26(3):375-8.
Angiogenesis is an essential process in the progression of malignant tumors and the most potent angiogenic factor is the vascular endothelial growth factor (VEGF). On the other hand, the CD34 is an endothelial antigen that has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoangiogenesis. In the present study we report the VEGF expression and its relationship with MVD, measured by CD34, in two lineages of non-small cell lung cancer (NSCL): low differentiated adenocarcinomas and epidermoid carcinomas, in order to consider the possibility of using the correlation between both antibodies as a prognostic factor. Tumor sections were stained by immunohistochemistry for CD34 and VEGF. The results showed that the mean value of VEGF for adenocarcinoma was significantly higher than the one for epidermoid carcinoma (p < 0.001). However, the mean of MVD did not show significant differences between both types of tumors. The conventional factors taken into consideration (age over 60, sex, and presence of lymph nodes) was not significantly related to the angiogenic factors examined. In conclusion, we could affirm that CD34 is a better prognostic marker of neoangiogenesis in NSCLC, because both types of tumors have the same clinical prognosis, and so we expected the same behaviour from both markers.
血管生成是恶性肿瘤进展过程中的一个重要过程，最有效的血管生成因子是血管内皮生长因子（VEGF）。另一方面，CD34是一种内皮抗原，已被用于突出微血管密度（MVD），作为新生血管形成程度的直接标志物。在本研究中，我们报告了非小细胞肺癌（NSCL）两个谱系（低分化腺癌和表皮样癌）中VEGF的表达及其与通过CD34测量的MVD的关系，以考虑将两种抗体之间的相关性用作预后因素的可能性。肿瘤切片通过免疫组织化学法对CD34和VEGF进行染色。结果显示，腺癌的VEGF平均值显著高于表皮样癌（p < 0.001）。然而，两种类型肿瘤的MVD平均值没有显著差异。所考虑的传统因素（年龄超过60岁、性别和淋巴结情况）与所检测的血管生成因子没有显著相关性。总之，我们可以肯定，CD34是NSCLC中新生血管形成更好的预后标志物，因为两种类型的肿瘤具有相同的临床预后，所以我们预期两种标志物会有相同的表现。
